Media coverage about Merus (NASDAQ:MRUS) has been trending positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Merus earned a media sentiment score of 0.30 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.9133488783898 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Merus stock opened at $18.05 on Friday. The stock has a market capitalization of $352.34, a P/E ratio of -7.71 and a beta of 0.08. Merus has a fifty-two week low of $13.23 and a fifty-two week high of $23.75.
MRUS has been the topic of a number of research analyst reports. BidaskClub upgraded Merus from a “strong sell” rating to a “sell” rating in a report on Saturday, December 30th. Royal Bank of Canada cut Merus from an “outperform” rating to a “sector perform” rating and set a $28.00 price objective on the stock. in a research note on Tuesday, January 2nd. Wedbush restated an “outperform” rating and set a $32.00 price objective on shares of Merus in a research note on Friday, January 12th. Finally, ValuEngine raised Merus from a “strong sell” rating to a “sell” rating in a research report on Monday, April 2nd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $30.00.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers.
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.